AAJ’s Protecting Patients—Handling Fungal Meningitis Outbreak Cases Webinar provides an in-depth look at the link between compounded steroid injections and the recent outbreak of fungal meningitis. Produced by the New England Compounding Company, the epidural steroid injections may have potentially exposed as many as 14,000 patients and have forced hospitals and care facilities to discontinue the use of this and other compounded steroids—leaving many without treatment options. This rare form of meningitis, an infection of the membrane covering the brain and spinal cord, has an incubation period of up to one month and has been tied to over 20 deaths and nearly 300 infections in more than 10 states. Spinal injections are often used to treat chronic and severe back pain and serve as a good and non-addictive alternate to prescription drugs. Join the webinar faculty to explore litigation strategies and updated information, and better understand the cause of the outbreak and how the New England Compounding Company, CDC, and FDA have responded.
Gale D. Pearson, MN
The Defendant, New England Compounding Company (NECC)—Business Dealings, Properties and Assets, and Past Issues Involving NECC
Michael R. Hugo, MA
Theories of Liability and Regulatory Oversight of Compounding
Robert K. Jenner, MD
Meningitis: The Medicine—Incubation, Morbidity, and Mortality
Elizabeth Peterson, MN
Question and Answer Session
Contribute to the AAJ Education Fund
Please consider a donation to the AAJ Education Fund 501(c)(3). Contributions support educational programs and activities to preserve and protect the civil justice system.
Learn more »